SCHEMBL2057039

SCHEMBL2057039

C#COC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 5/20 0.72
ADORA1 P30542 3/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
ADORA3 P0DMS8 2/20 0.70
ADORA2A P29274 2/20 0.70
ADORA2B P29275 2/20 0.70
DPP4 P27487 1/20 0.70
MEN1 O00255 1/20 0.70
SLC28A1 O00337 1/20 0.70
MAP3K7 O43318 1/20 0.70
SLC28A2 O43868 1/20 0.70
GAPDH P04406 1/20 0.70
MAPK1 P28482 1/20 0.70
STAT6 P42226 1/20 0.70
PI4KA P42356 1/20 0.70
KMT2A Q03164 1/20 0.70
PI4K2B Q8TCG2 1/20 0.70
DOT1L Q8TEK3 1/20 0.70
SLC29A1 Q99808 1/20 0.70
PI4K2A Q9BTU6 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15798541 1.00 AHCY (0.72) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL15371596 1.00 AHCY (0.72) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL11443305 0.89 AHCY (0.70) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL18862676 0.87 AHCY (0.70) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL926262 0.87 AHCY (0.68) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL2113154 0.87 AHCY (0.70) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL10304700 0.87 AHCY (0.70) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL10997946 0.86 ADORA1 (0.76) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL12963362 0.86 ADORA1 (0.76) AHCYADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL5024895 0.86 ADORA1 (0.76) AHCYADORA1SMN1; SMN2ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3863609-A1 SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS University of Pittsburgh - Of the Commonwealth System of Higher Education (US) 2021-08-18 EP claimed
WO-2025096203-A1 TARGETING A CHIMERIC RNA FOR TREATING CANCER UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-05-08 WO disclosed
WO-2025027492-A1 CORONAVIRUS ANTIGEN VARIANTS PFIZER INC. (US) 2025-02-06 WO disclosed
WO-2024133160-A1 HEPATITIS B COMPOSITIONS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-06-27 WO disclosed
EP-4387596-A1 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME GlaxoSmithKline Biologicals SA (BE) 2024-06-26 EP disclosed
WO-2024113009-A1 AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY THE UNIVERSITY OF QUEENSLAND (AU) 2024-06-06 WO disclosed
WO-2024041772-A1 RSV-F PROTEINS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-02-29 WO disclosed
WO-2024041773-A1 RSV-F PROTEINS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-02-29 WO disclosed
WO-2024035952-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING AT ALTERNATIVE SPLICE SITES REMIX THERAPEUTICS INC. (US) 2024-02-15 WO disclosed
WO-2023242817-A2 RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-12-21 WO disclosed
EP-3188749-A1 TOLEROGENIC COMPOSITIONS AND METHODS Moderna Therapeutics, Inc. (US) 2017-07-12 EP disclosed
WO-2017112943-A1 METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES MODERNATX, INC. (US) 2017-06-29 WO disclosed
WO-2017106799-A1 POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE MODERNATX, INC. (US) 2017-06-22 WO disclosed
EP-3052521-A1 POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR Moderna Therapeutics, Inc. (US) 2016-08-10 EP disclosed
WO-2016036902-A1 TOLEROGENIC COMPOSITIONS AND METHODS MODERNA THERAPEUTICS, INC. (US) 2016-03-10 WO disclosed
WO-2015051214-A1 POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR MODERNA THERAPEUTICS, INC. (US) 2015-04-09 WO disclosed
US-20110020799-A1 Screening method for damaged DNA repairing substance NAGASAKI UNIVERSITY 2011-01-27 US disclosed
EP-0365849-B1 Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl adenosine derivatives MERRELL DOW PHARMA (US) 1994-09-14 EP disclosed
CN-1046334-A New 2 '-halogenated methylene, 2 '-vinylidene and 2 '-the ethynyl adenosine derivative MERRELL DOW PHARMA (US) 1990-10-24 CN disclosed
EP-0365849-A2 Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl adenosine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1990-05-02 EP disclosed